Rheumatoid arthritis

Applied Molecular Transport Announces Board Appointments

Retrieved on: 
Thursday, January 27, 2022 - 9:30pm

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of John W. Smither to its Board of Directors and Chair of its Audit Committee. AMT also announced that current Director, Graham K. Cooper, has been named Executive Chair and current Director, Helen S. Kim, has been named Lead Independent Director.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of John W. Smither to its Board of Directors and Chair of its Audit Committee.
  • Mr. Smither added, I am delighted to join the AMT Board of Directors during such a significant year for the company.
  • Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.
  • Active transport is an efficient mechanism that uses the cells own machinery to transport materials across the IE barrier.

Galvani Bioelectronics Announces World’s First Investigational Treatment of Rheumatoid Arthritis Using Splenic Nerve Stimulation

Retrieved on: 
Thursday, January 27, 2022 - 12:05am

Splenic nerve stimulation generates nerve signals to the spleen which in turn have been shown to shift splenic immune cells from a pro-inflammation to an inflammation-resolving state.

Key Points: 
  • Splenic nerve stimulation generates nerve signals to the spleen which in turn have been shown to shift splenic immune cells from a pro-inflammation to an inflammation-resolving state.
  • We look forward to bringing the wide-ranging potential of splenic nerve stimulation to the clinic as a hopeful new treatment option for people suffering with rheumatoid arthritis, said Stephen Gillett, President and COO of Verily and Galvani Board Director.
  • To learn more about Splenic Nerve Stimulation for RA, visit https://www.SplenicStimulationforRa.com/ or to see more about the clinical studies visit (US) NCT05003310 or (UK) NCT04955899 .
  • The Galvani Bioelectronics platform is available for investigational use only and it is not approved for use outside of clinical studies.

Medidata Expands and Strengthens Decentralized Clinical Trial (DCT) Capabilities Through Groundbreaking Partnership With Circuit Clinical

Retrieved on: 
Wednesday, January 26, 2022 - 2:00pm

Medidata , a Dassault Systmes company, today announced a groundbreaking and exclusive partnership with Circuit Clinical, an Integrated Research Organization (IRO).

Key Points: 
  • Medidata , a Dassault Systmes company, today announced a groundbreaking and exclusive partnership with Circuit Clinical, an Integrated Research Organization (IRO).
  • Additionally, patients will have the opportunity to provide ratings and reviews of their clinical trial experiences through Circuit Clinicals award-winning TrialJourney system.
  • The combined capabilities of Circuit Clinical and Medidatas software solutions will further the ability to deliver hybrid or fully decentralized trials through Circuit Clinicals Network Health Systems and patient engagement capabilities.
  • Circuit Clinical is committed to transforming the way physicians and their patients find, choose, and participate in clinical research.

Global Autoinjectors Market Insights, Competitive Landscape and Forecast Report 2022-2026: Technological Advancements Leading to Innovative Product Development - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 25, 2022 - 5:15pm

The "Autoinjectors- Market Insights, Competitive Landscape and Market Forecast-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autoinjectors- Market Insights, Competitive Landscape and Market Forecast-2026" report has been added to ResearchAndMarkets.com's offering.
  • Global Autoinjectors Market was valued at USD 1.80 billion in 2020, growing at a CAGR of 20.50% during the forecast period from 2021 to 2026 to reach USD 5.51 billion by 2026.
  • The autoinjectors market is estimated to register significant growth in the forecast period on account of growing need for emergency administration of therapeutic drugs.
  • However, the availability of alternative products such as conventional needles and syringes in the market may restrain the growth of the autoinjectors market during the forecast period.

CareMetx and United Rheumatology Partner to Better Support Patients Who Suffer From Numerous Chronic Inflammatory Diseases

Retrieved on: 
Monday, January 24, 2022 - 5:44pm

Through this partnership, CareMetx will activate their intelligent prescription management solutions for both pharmacy and medical benefit products within United Rheumatologys network of Providers.

Key Points: 
  • Through this partnership, CareMetx will activate their intelligent prescription management solutions for both pharmacy and medical benefit products within United Rheumatologys network of Providers.
  • In addition to increased care awareness among rheumatology patients, the solution will help more effectively communicate with rheumatology patients who may need ongoing support services.
  • United Rheumatology is the preeminent rheumatology care management organization, empowering rheumatologists nationwide to advance the standard of care while leading in the development of value-based precision medicine.
  • Through this exciting partnership with United Rheumatology, CareMetx is able to improve patient access to life-changing therapies, says Brock Rush, SVP & GM of CareMetx.

Outlook on the Rheumatoid Arthritis Drugs Global Market to 2027 - Increasing Predominance of Arthritis and Other Joint Problems Are Fuelling Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 24, 2022 - 3:04pm

Despite this, certain drugs are used to efficiently control the conditions of rheumatoid arthritis, which include disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs.

Key Points: 
  • Despite this, certain drugs are used to efficiently control the conditions of rheumatoid arthritis, which include disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs.
  • The increasing predominance of arthritis and other joint problems fuels the market for rheumatoid arthritis treatment.
  • Although the manufacturing of drugs is considered under essential services, still due to COVID-19, the global rheumatoid arthritis drugs market has been slightly affected.
  • But, medications like tocilizumab and hydroxychloroquine used to treat rheumatoid arthritis have been found to treat the novel coronavirus, further boosting the Rheumatoid Arthritis Drugs Market.

Global Musculoskeletal Partnering Deal Trends, Players and Financials Analysis Report 2021: Analyse Deals Entered into by the World's Leading Life Science Companies Since 2014 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 20, 2022 - 10:02am

The "Global Musculoskeletal Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Musculoskeletal Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Musculoskeletal Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals.
  • The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.
  • The report also includes numerous tables and figures that illustrate the trends and activities in Musculoskeletal partnering and dealmaking since 2014.

Grapefruit USA, Inc. Outlines 2022 Corporate Evolution

Retrieved on: 
Tuesday, January 18, 2022 - 11:00am

Upon Health Canada approval, expected by the end of Q1 2022, Grapefruit will launch sales of the Hourglass technology-based THC and CBD in Canada through its licensed distribution partner Medz Cannabis, Inc. and its manufacturing partner 6Pak.

Key Points: 
  • Upon Health Canada approval, expected by the end of Q1 2022, Grapefruit will launch sales of the Hourglass technology-based THC and CBD in Canada through its licensed distribution partner Medz Cannabis, Inc. and its manufacturing partner 6Pak.
  • Grapefruit continues to conduct discussions with its potential Canadian partner concerning the possibility of a joint venture and/or acquisition transaction.
  • Grapefruit will reach an agreement with the Canadian counterpart in the first or early second quarter of 2022 or will terminate the discussions.
  • Finally, no one besides Grapefruit or its authorized agents can manufacture, distribute or sell at retail Hourglass-based products, Yourist added.

Feinstein Institutes Bioelectronic Medicine Scientists Develop First-of-its-Kind Wireless Neuromodulation Device for Research

Retrieved on: 
Wednesday, January 19, 2022 - 3:00pm

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220119005185/en/
    Pictured is a second generation version of the wireless neuromodulation implantable mouse stimulator developed at the Feinstein Institutes.
  • (Credit: Feinstein Institutes)
    Bioelectronic medicine is a new approach to treating and diagnosing disease and injury that has emerged from the Feinstein Institutes labs.
  • The teams research builds off previous studies unveiled by the Feinstein Institutes the global scientific home of bioelectronic medicine.
  • Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine.

AscellaHealth Designates Preferred Status to Leading Pharmacies for Home Infusion Pharmacy Network, Enhances Site of Care Optimization

Retrieved on: 
Tuesday, January 18, 2022 - 3:00pm

AscellaHealth , a global specialty pharmacy and healthcare solutions company, is pleased to announce that Amber Specialty Pharmacy , AcariaHealth and BioMatrix Specialty Pharmacy are preferred partners within its Home Infusion Pharmacy Network.

Key Points: 
  • AscellaHealth , a global specialty pharmacy and healthcare solutions company, is pleased to announce that Amber Specialty Pharmacy , AcariaHealth and BioMatrix Specialty Pharmacy are preferred partners within its Home Infusion Pharmacy Network.
  • These designations are part of AscellaHealths Site of Care Optimization (SOC) initiative and overall strategies designed to cut costs without compromising quality of care, which are critical for third-party payers.
  • As part of our mission to help our clients better manage the high costs of specialty medication, this initiative exemplifies our efforts to increase care accessibility by encouraging the use of clinically appropriate, lower-cost care settings.
  • The extensive range of these pharmacy sites that are dedicated to infusion therapy creates a better patient experience and improves outcomes.